Investing.com -- CytoMed Therapeutics Limited (NASDAQ:GDTC) stock surged 9.6% on Monday after the company announced a partnership with Universiti Malaya Medical Centre to establish a first-in-human Phase I clinical trial in Malaysia.
The Singapore-based clinical stage biopharmaceutical company will investigate the safety and efficacy of its patented allogeneic unmodified Gamma Delta T cells (CTM-GDT) for cancer patients with limited treatment options. This initiative complements CytoMed’s ongoing Phase I chimeric antigen receptor T clinical trial at National University Hospital Singapore.
CytoMed’s Chairman, Peter Choo, emphasized that the collaboration "will pave the way for an affordable cancer immunotherapy option to patients with limited treatment alternatives." Unlike most immunotherapies that use the patient’s own cells (autologous), CytoMed’s technology uses specialized T cells from healthy donors (allogeneic), which the company claims is more cost-effective and accessible.
The company’s approach has shown promise in previous research. CytoMed co-authored a September 2025 publication with The University of Texas, MD Anderson Cancer Center suggesting potential for treating acute myeloid leukemia with its CTM-GDT therapy.
Professor Dr. Lim Soo Kun, Head of Clinical Investigation Centre of UMMC, stated that the partnership "reflects our shared commitment to advancing clinical innovation for the benefit of our community."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








